Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement
Charlotte Rigaud,
Samuel Abbou,
Stephane Ducassou,
Mathieu Simonin,
Lou Le Mouel,
Victor Pereira,
Stephanie Gourdon,
Anne Lambilliotte,
Birgit Geoerger,
Veronique Minard-Colin,
Laurence Brugieres
Affiliations
Charlotte Rigaud
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Samuel Abbou
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Stephane Ducassou
Department of Pediatric Oncology and Hematology, Bordeaux University hospital, Bordeaux
Mathieu Simonin
Department of Pediatric Oncology and Hematology, Armand Trousseau Hospital- APHP, Paris
Lou Le Mouel
Department of Pediatric Hematology, Robert Debré Hospital- APHP, Paris
Victor Pereira
Department of Pediatric Oncology and Hematology, Besançon University Hospital, Besançon
Stephanie Gourdon
Department of Pediatric Oncology and Hematology, Saint-Denis de la Réunion University Hospital
Anne Lambilliotte
Department of Pediatric Hematology, Lille University Hospital, Lille
Birgit Geoerger
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Veronique Minard-Colin
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
Laurence Brugieres
Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif
